modelN06AX22

Diagram of N06AX22

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Agomelatine
ATC code:N06AX22
route:oral
compartments:1
dosage:25mg
volume of distribution:35L
clearance:1100mL/min
other parameters in model implementation

Agomelatine is an antidepressant that acts as an agonist at melatonergic MT1 and MT2 receptors and as an antagonist at 5-HT2C serotonin receptors. It is used primarily in the treatment of major depressive disorder in adults. Agomelatine is approved in several countries for clinical use in depression.

Pharmacokinetics

Pharmacokinetic parameters summarized for healthy adult subjects after oral administration as single and multiple doses.

References

  1. Xie, F, et al., & Cheng, Z (2019). A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers. British journal of clinical pharmacology 85(5) 1003–1014. DOI:10.1111/bcp.13902 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30761579

  2. Song, L, et al., & Wang, L (2014). Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. Journal of clinical pharmacy and therapeutics 39(2) 204–209. DOI:10.1111/jcpt.12118 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24372004

  3. ElKady, EF, et al., & Farouk, F (2018). Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 1102-1103 135–142. DOI:10.1016/j.jchromb.2018.10.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30388703

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)